Meeting
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
Authors
Marwan Fakih
City of Hope National Medical Center, Duarte, CA
Marwan Fakih , Jaideep Singh Sandhu , Chongkai Wang , Ching Ouyang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 72)
DOI
10.1200/JCO.2021.39.3_suppl.72
Abstract #
72
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Jeddeo Paul
Poster
2020 ASCO Quality Care Symposium
Effectiveness of immunotherapy given to cancer patients in the hospitalized setting.
First Author: Mojisola O Araoye
Poster
2019 ASCO Annual Meeting
Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).
First Author: Eric Jeffrey Sherman
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna